{"id":"anti-tumor-necrosis-factor-alpha-agents","safety":{"commonSideEffects":[{"rate":"null","effect":"Infections"},{"rate":"null","effect":"Allergic reactions"},{"rate":"null","effect":"Increased risk of lymphoma"},{"rate":"null","effect":"Neurological events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TNF-alpha is a cytokine that promotes inflammation and is involved in the pathogenesis of various autoimmune and inflammatory diseases. By blocking TNF-alpha, anti-TNF agents can reduce inflammation and slow disease progression.","oneSentence":"Anti-tumor necrosis factor alpha agents work by blocking the action of tumor necrosis factor-alpha (TNF-alpha), a protein involved in systemic inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:10:22.669Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT07453628","phase":"","title":"Association of Erectile Dysfunction With Neuropathic Pain, Disease Activity, and Functional Status in Male Patients With Axial Spondyloarthritis: A Cross-Sectional Observational Study","status":"COMPLETED","sponsor":"Altuğ Güner","startDate":"2021-02-03","conditions":"Ankylosing Spondylitis, Sexual Dysfunction","enrollment":90},{"nctId":"NCT00385086","phase":"PHASE3","title":"Lumbar Spinal Fibrosis and TNF Alpha Inhibition","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-02","conditions":"Post Operative Sciatica by Lumbar Spinal Fibrosis","enrollment":38},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT05428488","phase":"PHASE3","title":"Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2022-11-28","conditions":"Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT07181694","phase":"PHASE1","title":"A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects","status":"RECRUITING","sponsor":"Biocad","startDate":"2025-03-12","conditions":"Healthy Adult Male","enrollment":444},{"nctId":"NCT06418529","phase":"","title":"A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-15","conditions":"Rheumatoid Arthritis","enrollment":21340},{"nctId":"NCT03915964","phase":"PHASE4","title":"A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-25","conditions":"Rheumatoid Arthritis","enrollment":2663},{"nctId":"NCT04086745","phase":"PHASE4","title":"A Study of Baricitinib in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-14","conditions":"Rheumatoid Arthritis","enrollment":1317},{"nctId":"NCT05080218","phase":"PHASE4","title":"COVID-19 VaccinE Response in Rheumatology Patients","status":"COMPLETED","sponsor":"Jeffrey Curtis","startDate":"2021-11-15","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis","enrollment":841},{"nctId":"NCT05599347","phase":"PHASE2","title":"Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2023-04-24","conditions":"Crohn's Disease Relapse, Biological Substance; Adverse Effect","enrollment":180},{"nctId":"NCT06653634","phase":"PHASE4","title":"Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-10-24","conditions":"Juvenile Idiopathic Arthritis","enrollment":150},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT06601595","phase":"","title":"Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital","status":"NOT_YET_RECRUITING","sponsor":"Mohamed Nasr","startDate":"2024-10","conditions":"Inflammatory Bowel Disease (IBD), Spondylarthropathies, TNF-alpha Inhibitors","enrollment":100},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT03652961","phase":"PHASE4","title":"Rheumatoid Arthritis Memory B Cells and Abatacept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-02","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT06177405","phase":"","title":"Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors","status":"COMPLETED","sponsor":"Institute of Biomedical Chemistry, Russia","startDate":"2021-01-15","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT05702879","phase":"","title":"Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success","status":"UNKNOWN","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-09-06","conditions":"Ulcerative Colitis","enrollment":240},{"nctId":"NCT02144857","phase":"PHASE4","title":"Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2014-05-30","conditions":"Psoriasis","enrollment":200},{"nctId":"NCT00042406","phase":"PHASE2, PHASE3","title":"Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker","status":"TERMINATED","sponsor":"Genmab","startDate":"2002-03-04","conditions":"Rheumatoid Arthritis","enrollment":83},{"nctId":"NCT05540743","phase":"PHASE4","title":"Biologic Therapy in Pediatric JIA Uveitis","status":"UNKNOWN","sponsor":"Kasr El Aini Hospital","startDate":"2022-07-01","conditions":"Juvenile Idiopathic Arthritis Associated Uveitis","enrollment":250},{"nctId":"NCT02552212","phase":"PHASE3","title":"Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2015-09","conditions":"Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA","enrollment":317},{"nctId":"NCT04798287","phase":"","title":"Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-10","conditions":"Rheumatoid Arthritis","enrollment":105711},{"nctId":"NCT03419143","phase":"","title":"Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-03-02","conditions":"Psoriatic Arthritis (PsA)","enrollment":190},{"nctId":"NCT01881308","phase":"PHASE4","title":"Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Diakonhjemmet Hospital","startDate":"2013-06-17","conditions":"Rheumatoid Arthritis","enrollment":320},{"nctId":"NCT04772248","phase":"","title":"Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-02-22","conditions":"Rheumatoid Arthritis","enrollment":105711},{"nctId":"NCT04529902","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - TNFi vs Abatacept","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-08-17","conditions":"Rheumatoid Arthritis","enrollment":63013},{"nctId":"NCT00837434","phase":"PHASE4","title":"Anti-TNF Agents for the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":63},{"nctId":"NCT01960855","phase":"PHASE2","title":"A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-10","conditions":"Rheumatoid Arthritis","enrollment":276},{"nctId":"NCT04953871","phase":"PHASE4","title":"Enthesitis Assessment Before and After Anti-Tumor Necrosis Factor Treatment in Spondyloarthritis","status":"COMPLETED","sponsor":"Gunay ER","startDate":"2017-01","conditions":"Spondyloarthritis, Enthesitis, Anti-Tumor Necrosis Factor Drugs","enrollment":31},{"nctId":"NCT02687620","phase":"","title":"Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study","status":"UNKNOWN","sponsor":"Izmir Katip Celebi University","startDate":"2014-09","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":180},{"nctId":"NCT03162796","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-08-24","conditions":"Arthritis, Psoriatic","enrollment":383},{"nctId":"NCT02505542","phase":"PHASE3","title":"Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2015-07","conditions":"Axial Spondyloarthrithis, Ankylosing Spondylitis","enrollment":736},{"nctId":"NCT01548768","phase":"PHASE4","title":"RHYTHM (Formerly Escape II Myocardium)","status":"COMPLETED","sponsor":"Columbia University","startDate":"2011-10-10","conditions":"Rheumatoid Arthritis","enrollment":149},{"nctId":"NCT02492217","phase":"PHASE4","title":"Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients","status":"COMPLETED","sponsor":"Universidade Nova de Lisboa","startDate":"2015-05","conditions":"Ankylosing Spondylitis","enrollment":69},{"nctId":"NCT02353780","phase":"PHASE4","title":"Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept","status":"TERMINATED","sponsor":"Dr. Larry W. Moreland","startDate":"2015-03","conditions":"Rheumatoid Arthritis (RA)","enrollment":10},{"nctId":"NCT00965666","phase":"EARLY_PHASE1","title":"Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2005-10","conditions":"Fanconi Anemia","enrollment":3},{"nctId":"NCT04115423","phase":"","title":"A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-04-01","conditions":"Infection, Rheumatoid Arthritis","enrollment":9508},{"nctId":"NCT03729674","phase":"","title":"Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2018-11-26","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Ulcerative Colitis","enrollment":800},{"nctId":"NCT01060098","phase":"","title":"T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2010-04","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":48},{"nctId":"NCT03886233","phase":"","title":"Treatment Outcome of Uveitis in Autoimmune Diseases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03","conditions":"Autoimmune Uveitis","enrollment":1},{"nctId":"NCT03273088","phase":"PHASE1","title":"Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects","status":"COMPLETED","sponsor":"AryoGen Pharmed Co.","startDate":"2016-12-04","conditions":"Phase 1, Bioequivalence","enrollment":34},{"nctId":"NCT02242474","phase":"PHASE4","title":"Anti-TNFα Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"CHU de Quebec-Universite Laval","startDate":"2015-07","conditions":"Rheumatoid Arthritis","enrollment":660},{"nctId":"NCT02862574","phase":"PHASE2","title":"Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-12-15","conditions":"Rheumatoid Arthritis","enrollment":15},{"nctId":"NCT03470688","phase":"","title":"Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents","status":"UNKNOWN","sponsor":"Opal Rheumatology Ltd.","startDate":"2018-03-01","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis","enrollment":5000},{"nctId":"NCT02765594","phase":"PHASE4","title":"Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2016-06","conditions":"Primary IgA Nephropathy","enrollment":98},{"nctId":"NCT01400516","phase":"PHASE4","title":"Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-08","conditions":"Rheumatoid Arthritis","enrollment":26},{"nctId":"NCT01313221","phase":"PHASE3","title":"Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-04","conditions":"Psoriasis","enrollment":310},{"nctId":"NCT01974869","phase":"","title":"Anti Tumor Necrosis Factor Alpha Agents and Surgical Stress Response","status":"COMPLETED","sponsor":"El-Hussuna, Alaa, M.D.","startDate":"2014-03","conditions":"Inflammatory Bowel Diseases","enrollment":47},{"nctId":"NCT02073526","phase":"","title":"Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2013-05","conditions":"Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis","enrollment":1230},{"nctId":"NCT02878161","phase":"PHASE4","title":"Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From \"Real World\"","status":"UNKNOWN","sponsor":"Fen Li","startDate":"2016-01","conditions":"Rheumatoid Arthritis","enrollment":240},{"nctId":"NCT01350804","phase":"PHASE3","title":"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-09","conditions":"Rheumatoid Arthritis","enrollment":551},{"nctId":"NCT02754869","phase":"","title":"Magnetic Resonance Imaging Assessment of Small Bowel Motility","status":"UNKNOWN","sponsor":"University College, London","startDate":"2011-02","conditions":"Motility Disorder of Intestine","enrollment":172},{"nctId":"NCT01356758","phase":"","title":"Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2011-03","conditions":"Psoriasis, Atopic Dermatitis, Atherosclerosis","enrollment":126},{"nctId":"NCT02456363","phase":"PHASE2","title":"Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis","status":"UNKNOWN","sponsor":"Chung Shan Medical University","startDate":"2009-11","conditions":"Ankylosing Spondylitis","enrollment":300},{"nctId":"NCT00006064","phase":"","title":"The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-06","conditions":"HIV Infections, HIV Wasting Syndrome, Lipodystrophy","enrollment":100},{"nctId":"NCT01077362","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-03","conditions":"Arthritis, Psoriatic","enrollment":312},{"nctId":"NCT01072058","phase":"PHASE4","title":"Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2008-02","conditions":"Arthritis, Rheumatoid, Spondylitis, Ankylosing","enrollment":100},{"nctId":"NCT00796705","phase":"PHASE4","title":"Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-11","conditions":"Rheumatoid Arthritis","enrollment":13},{"nctId":"NCT00925249","phase":"","title":"Comparison of the Tuberculin Skin Test (TST) and QuantiFERON ®-TB Gold Test (QFT-G) In Patients With Rheumatoid Arthritis Being Considered for Anti-TNF-Alpha Therapy","status":"UNKNOWN","sponsor":"Walter Reed Army Medical Center","startDate":"2009-05","conditions":"Rheumatoid Arthritis, Tuberculosis","enrollment":90},{"nctId":"NCT00141791","phase":"PHASE2","title":"Study Evaluating Etanercept in Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-05","conditions":"Asthma","enrollment":120},{"nctId":"NCT00000860","phase":"","title":"The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Mycobacterium Avium-Intracellulare Infection, HIV Infections","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":182,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Biologics"],"phase":"phase_2","status":"active","brandName":"Anti-tumor necrosis factor alpha agents","genericName":"Anti-tumor necrosis factor alpha agents","companyName":"El-Hussuna, Alaa, M.D.","companyId":"el-hussuna-alaa-m-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-tumor necrosis factor alpha agents work by blocking the action of tumor necrosis factor-alpha (TNF-alpha), a protein involved in systemic inflammation. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}